Q-omics provides the consensus-scored PAQR5 profile across patient tissues and cancer cell-line models. PAQR5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PAQR5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PAQR5 RNA expression shows 17,844 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where PAQR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAQR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAQR5 survival associations across molecular data types. PAQR5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAQR5 RNA expression–survival associations across cancer types. High PAQR5 expression shows unfavorable associations in PAAD, LIHC, UCEC and UVM, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PAQR5 RNA expression.
This table summarizes PAQR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PAQR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAQR5 shows lower tumor expression in COAD, KIRC, KIRP, LUAD and THCA and higher tumor expression in LIHC. The COAD box plot shows higher PAQR5 RNA expression in normal versus tumor tissue (log2 FC = −2.169, t-test p < 0.001).
This table shows molecular features associated with PAQR5 in patient tissues and cancer cell lines. In patient samples, PAQR5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAQR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
